First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis

OBJECTIVE: Prognosis of patients with irresectable cholangiocarcinoma is still poor. The ABC-02 trial established the current first line (1L) standard systemic chemotherapy (CT) with gemcitabine/platinum derivate for advanced cholangiocarcinoma. However, the majority of patients needed therapy adapt...

Descripción completa

Detalles Bibliográficos
Autores principales: Möhring, Christian, Feder, Jan, Mohr, Raphael U., Sadeghlar, Farsaneh, Bartels, Alexandra, Mahn, Robert, Zhou, Taotao, Marinova, Milka, Feldmann, Georg, Brossart, Peter, von Websky, Martin, Matthaei, Hanno, Manekeller, Steffen, Glowka, Tim, Kalff, Jörg C., Weismüller, Tobias J., Strassburg, Christian P., Gonzalez-Carmona, Maria A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631360/
https://www.ncbi.nlm.nih.gov/pubmed/34858809
http://dx.doi.org/10.3389/fonc.2021.717397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631360/
https://www.ncbi.nlm.nih.gov/pubmed/34858809
http://dx.doi.org/10.3389/fonc.2021.717397

Ejemplares similares